Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Leukemia, Lymphoma
Interventions: Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pelvic Organ Prolapse, Prolapse
Interventions: Reia System, Standard of Care Pessary; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 6 more

Conditions: Hypoglycemia
Interventions: Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: TAS-102, Placebo; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma (Diagnosis)
Interventions: Dexamethasone (0.6mg/kg; Max 16mg) Once Daily, Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours, Methylprednisolone; Drug
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 3 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hydrocephalus
Interventions: FlowSense; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
Interventions: VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma Multiforme
Interventions: ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anaplastic Astrocytoma, Glioblastoma
Interventions: Sunitinib Malate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Task-Specific Focal Dystonia
Interventions: ExAblate Transcranial treatment; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Survivors of Childhood Cancer, Alopecia
Interventions: Oral Minoxidil, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Ixabepilone, Cisplatin; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19, SARS-CoV 2
Interventions: COVID-19 Convalescent Plasma; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
U.S. locations: 6
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more

Conditions: Lower-Limb Amputation
Interventions: Exercise self-management, Attention control; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Abdominal Adhesions
Interventions: Transgastric diagnostic peritoneoscopy with laparoscopic assistance; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: IMBRUVICA (Treatment A), Ibrutinib (Treatment B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia, Bipolar Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 37
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Healthy
Interventions: 3% SPL7013 Gel (VivaGel), Placebo Gel, HEC Placebo Gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: Cystitis, Interstitial, Painful Bladder Syndrome
Interventions: LiRIS®, LiRIS Placebo; Combination Product
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 31
States / cities: Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more

Conditions: Hodgkins Lymphoma, Non-Hodgkin Lymphoma
Interventions: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment

G-Pen™ for Hypoglycemia Rescue in T1D Patients

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

EVD Drainage Data and Intracranial Pressure (ICP) Measurements

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD)

A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

Phase I Combination Ixabepilone + Cisplatin

Oral Testosterone for the Treatment of Hypogonadism

Convalescent Plasma for the Treatment of Patients With COVID-19

Walking Exercise Sustainability Through Telehealth for Veterans With Lower-limb Amputation

Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Aripiprazole Open-Label, Safety and Tolerability Study

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma